BeyondSpring
BeyondSpring reported revenue of $0 million in fiscal 2025. Free cash flow was −$20 million.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What BeyondSpring does
BeyondSpring is a drug developer in the clinical stage: it has no approved medicines and earns no revenue from product sales. Its main drug candidate is Plinabulin, a small-molecule cancer drug derived from a compound found in marine microorganisms. The company says Plinabulin works by helping immune cells called dendritic cells mature, which may help patients whose cancer has stopped responding to immunotherapy, and that it can also reduce a drop in white blood cells caused by chemotherapy.
Its most advanced work is in non-small cell lung cancer, the most common type of lung cancer. A completed late-stage trial, DUBLIN-3, enrolled 559 patients and tested Plinabulin with the chemotherapy drug docetaxel against docetaxel alone. BeyondSpring plans to seek approval in China and to run a new global trial. Hospitals in China and the US are also testing Plinabulin with other cancer drugs. It has three more drug candidates at an early, pre-clinical stage, and says it plans to look for a partner to sell Plinabulin outside China if it is approved.
BeyondSpring founded SEED Therapeutics, which works on a way of breaking down disease-causing proteins and has partnerships with Eli Lilly and Eisai. BeyondSpring owns about 38.03% of SEED and has agreed to sell part of that stake. The company is incorporated in the Cayman Islands, has its main office in New Jersey and offices in China, and had 44 full-time employees in early 2026, including 34 at SEED.
Its biggest risks, as it describes them
- Its reliance on Plinabulin: if trials fail or approval is delayed or refused, the business would be badly harmed.
- It has lost money every year since it began and needs more funding, which could dilute shareholders.
- Regulators in the US, China or Europe may decide its trial results are not strong enough and ask for more trials.
- It has no sales and marketing team of its own and plans to rely on partners to sell any approved drug.
- Its reliance on outside firms to run its clinical trials and studies.
Income statement
BeyondSpring lost money in fiscal 2025: a net loss of $1 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 72 | 37 | — | 3 | 13 |
| Debt incl. finance leases | 2 | 0 | 0 | 0 | 0 |
| Net debt (negative means net cash) | −71 | −37 | — | −3 | −13 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.1x | — | — | — | — |
| Interest coverage | −761.4x | −2,190.5x | — | — | — |
| Current ratio | 5.0x | 5.2x | 2.3x | 2.6x | 1.5x |
| Quick ratio | 5.0x | 5.2x | 2.3x | 2.6x | 1.5x |
Cash flow
Projections
Project BeyondSpring's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of BeyondSpring reported buying or selling its shares on the open market between November 20, 2025 and November 19, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | — | — |
| Altman Z'' | −54.17 | −37.37 | −52.32 |
| Accruals ratio | −12.8% | 18.0% | 62.3% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Fail | Fail |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | — | — | — |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Fail | Fail |
| F-score | — | — | — |
Compare
Put BeyondSpring side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| BeyondSpring | FY25 | — | — | — | — | — | — | |
| Aardvark Therapeutics | FY25 | — | — | — | — | — | — | Compare |
| ABVC BioPharma | FY25 | −41.9% | −2,416.0% | — | — | — | — | Compare |
| Acadia Pharmaceuticals | FY25 | 11.9% | 9.8% | 9.8% | — | — | — | Compare |
| Aclaris Therapeutics | FY25 | −58.2% | −975.9% | −603.4% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Revenue growth | — | — | — | — | — | 650.6% | 0.0% | −100.0% | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | 10 | 89 | 52 | 31 | 42 | 37 | 26 | 7 | 3 | 4 |
| Operating income | −12 | −98 | −58 | −40 | −64 | −66 | −37 | −15 | −9 | −9 |
| Net income | −12 | −92 | −55 | −38 | −61 | −64 | −33 | −21 | −11 | −1 |
| Diluted EPS (US$) | −0.75 | −4.40 | −2.42 | −1.55 | −2.03 | −1.64 | — | — | — | — |
| Diluted shares (millions) | 16 | 21 | 23 | 25 | 30 | 39 | 39 | — | — | — |
| Cash flow | ||||||||||
| Cash from operations | −14 | −29 | −40 | −48 | −44 | −47 | −28 | −16 | −16 | −20 |
| Capital expenditure | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 |
| Free cash flow | −14 | −29 | −40 | −48 | −44 | −50 | −28 | −17 | −17 | −20 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | — | 23 | 7 | 2 | 8 | 3 | 2 | 1 | 2 | 1 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 12 | 31 | 4 | 36 | 110 | 72 | 37 | — | 3 | 13 |
| Debt incl. finance leases | — | — | — | 1 | 2 | 2 | 0 | 0 | 0 | 0 |
| Total assets | 15 | 33 | 7 | 45 | 117 | 82 | 46 | 25 | 34 | 26 |
| Total liabilities | 3 | 5 | 16 | 13 | 25 | 55 | 49 | 48 | 49 | 50 |
| Shareholders' equity | 12 | 27 | −8 | 30 | 88 | 27 | −6 | −27 | −33 | −32 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | −35,672.8% | −4,903.0% | −2,756.4% | — | — | — |
| Net margin | — | — | — | — | −33,873.9% | −4,750.5% | −2,463.3% | — | — | — |
| Free cash flow margin | — | — | — | — | −24,331.7% | −3,707.3% | −2,035.4% | — | — | — |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | −3,056.8% | −2,035.4% | — | — | — |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −113.8% | −467.8% | −568.3% | −338.4% | −102.8% | −111.6% | −321.5% | — | — | — |
| Return on assets | −92.8% | −384.5% | −275.1% | −147.6% | −75.5% | −64.6% | −52.0% | −59.2% | −37.6% | −3.3% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |